Opaleye Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Opaleye Management’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-315,550	Closed	-$41.5M	–	74
2020 Q4	$41.5M	Hold	315,550	–	–	5.42%	3
2020 Q3	$15.9M	Hold	315,550	–	–	3.12%	10
2020 Q2	$14.6M	Hold	315,550	–	–	2.96%	9
2020 Q1	$15.5M	Hold	315,550	–	–	4.1%	7
2019 Q4	$18.1M	Buy	315,550 +10,000	+3%	+$495K	3.55%	9
2019 Q3	$11M	Hold	305,550	–	–	3.97%	5
2019 Q2	$9.5M	Buy	305,550 +105,550	+53%	+$2.86M	2.89%	15
2019 Q1	$4.69M	Buy	200,000 +60,000	+43%	+$963K	1.3%	32
2018 Q4	$1.93M	Buy	+140,000	New	+$1.77M	0.72%	34

Opaleye Management's EIDX Position: Q1 2021 in Review

Opaleye Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 315,550 shares — an estimated $41.5M sold.

Opaleye Management first reported a position in EIDX in Q4 2018 and held it in 9 quarters. The position peaked at $41.5M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Opaleye Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Opaleye Management sold 315,550 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $41.5M.
Opaleye Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2018 and held it in 9 quarters.
Opaleye Management's Eidos Therapeutics, Inc. Common Stock position peaked at $41.5M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Opaleye Management's 13F filing for Q1 2021, filed 18 May 2021.